

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTDate Submitted: 6/2/2004

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/091,578 |
| Filing Date | 10/6/1998 |
| First Named Inventor | Edwin L. Madison |
| Group Art Unit | 1644 |
| Examiner Name | Schwadron, Ronald B. |
| Attorney Docket Number | 022726-0201 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| <u>mm/</u> | A1 | EPO | 0 271 227 B1 | | <u>LABOUR et al.</u> The General Hospital Corp. | 09.06.93 | | |
| | | | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| <u>mm/</u> | A2 | Aki et al., "Interferon- γ induces different subunit organizations and functional diversity of proteasomes," <i>J. Biochem.</i> 115:257-269 (1994) | |
| | A3 | Backstrom et al., "Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli," <i>gene</i> , 165:163-171 (1995) | |
| | A4 | Barbas III et al., "High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site," <i>Proc. Natl. Acad. Sci. USA</i> 90:10003-10007 (November 1993) | |
| <u>mm/</u> | A5 | Barbars, Carlos F., "Recent advances in phage display," <i>Current Opinion in Biotech.</i> 4:526-530 (1993) | |
| <u>mm/</u> | A6 | Bass et al., "A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor," <i>Proc. Natl. Acad. Sci. USA</i> 88:4498-4502 (May 1991) | |
| <u>mm/</u> | A7 | Bassel-Duby et al., "Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor," <i>Journ. Of Biol. Chem.</i> 267(4):9668-9677 (1992) | |

already of record


DLMR254013.1

Examiner
SignatureDate
Considered2/5/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: _____

(use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/091,578 |
| Filing Date | 10/6/1998 |
| First Named Inventor | Edwin L. Madison |
| Group Art Unit | 1644 |
| Examiner Name | Schwadron, Ronald B. |
| Attorney Docket Number | 022726-0201 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | A8 | Bei et al., "Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein," <i>Jour. Immunol. Methods</i> 186:245-255 (1995) | |
| MJ | A9 | Bode et al., "Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation," <i>Circulation</i> 84(2):805-813 (August 1991) | |
| MJ | A10 | Browne et al., "A tissue-type plasminogen activator mutant with prolonged clearance in vivo," <i>The Journal of Biol. Chem.</i> 263(4):1599-1602 (1988) | |
| MJ | A11 | Charo et al., "The vitronectin receptor $\alpha_5\beta_3$ binds fibronectin and acts in concert with $\alpha_5\beta_1$ in promoting cellular attachment and spreading on fibronectin," <i>The Journal of Cell Biology</i> 111(6,1):2795-2800 (1990) | |
| | A12 | Cheon et al., "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <i>Proc. Natl. Acad. Sci. USA</i> 91:989-993 (February 1994) | |
| MJ | A13 | Coux et al., "Structure and functions of the 20S and 26S proteasomes," <i>Annu. Rev. Biochem.</i> 65:801-47 (1996) | |
| | A14 | Cunningham et al., "Engineering human prolactin to bind to the human growth hormone receptor," <i>Science</i> 247:1461-1465 (1990) | |
| MJ | A15 | Dahlmann et al., "Purification and characterization of a multicatalytic high-molecular-mass proteinase from rat skeletal muscle," <i>Biochem.</i> 228:161-170 (1985) | |
| MJ | A16 | Dahlmann et al., "Studies on the activation by ATP of the 26S proteasome complex from rat skeletal muscle," <i>Biochem. J.</i> 309:195-202 (1995) | |
| MJ | A17 | Dahlmann et al., "The multicatalytic proteinase: a high- M_r endopeptidase," <i>BJ Letters</i> 255:750-1 (1988) | |
| MJ | A18 | De Lorimier et al., "NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus," <i>Biochemistry</i> 33:2055-2062 (1994) | |

already
at recordalready
at
recordportions
your excludable
due to
prior art

DLMR254013.1


Examiner
SignatureDate
Considered

2/5/2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/091,578 |
| Filing Date | 10/6/1998 |
| First Named Inventor | Edwin L. Madison |
| Group Art Unit | 1644 |
| Examiner Name | Schwadron, Ronald B. |
| Attorney Docket Number | 022726-0201 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|--------------------------|
| MJ | A19 | Dewerchin et al., "Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo," <i>Blood</i> 78(4):1005-1018 (August 15) | |
| | A20 | Duarte et al., "Multipeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop," <i>AIDS Research and Human Retroviruses</i> 10(3):235-243 (1994) | already ot ✓ clond |
| | A21 | Gething et al., "Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain," <i>EMBO J.</i> 7(9):2731-40 (September 1988) | ✓ |
| MJ | A22 | Hashino et al., "Engineering of artificial cell adhesion proteins by grafting the arg-gly-asp cell adhesive signal to a calpastatin segment," <i>J. Biochem.</i> 112:547-551 (1992) | |
| | A23 | Hearst et al., "GRAFTER: a computational aid for the design of novel proteins," <i>Protein Engin.</i> 7(12):1411-1421 (1994) | already ot ✓ clond |
| MJ | A24 | Janin et al., "The structure of protein-protein recognition sites," <i>The Journal of Biological Chemistry</i> 265(27):16027-16030 (1990) | |
| MJ | A25 | Johannessen et al., "Fibrin affinity and clearance of t-PA deletion and substitution analogues," <i>Throm. Haemost.</i> 63:54-59 (1990) | |
| MJ | A26 | Kagitani et al., "Expression in E. Coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity," <i>FEBS</i> 189(1):145-149 (September 1985) | |
| MJ | A27 | Kalyan et al., "Structure-function analysis with tissue-type plasminogen activator," <i>The Journal of Biological Chemistry</i> 263(8):3971-3978 (March 15, 1988) | |
| MJ | A28 | Kohda et al., "Tertiary structure of mouse epidermal growth factor determined by two-dimensional H NMR," <i>J. Biochem.</i> 103:741-743 (1988) | |
| MJ | A29 | Kunkel et al., "Rapid and efficient site-specific mutagenesis without phenotypic selection," <i>Proc. Natl. Acad. Sci. USA</i> 82:488-492 (January 1985) | |
| MJ | A30 | Larsen et al., "Variants of human tissue-type plasminogen activator," <i>The Journal of Biological Chemistry</i> 263(2):1023-1029 (January 15, 1988) | |

DLR254013.1


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/091,578 |
| Filing Date | 10/6/1998 |
| First Named Inventor | Edwin L. Madison |
| Group Art Unit | 1644 |
| Examiner Name | Schwadron, Ronald B. |
| Attorney Docket Number | 022726-0201 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|-----------------------------|
| ms/ | A31 | Madison et al., "Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1," <i>Proc. Natl. Acad. Sci. USA</i> 87:3530-3533 (May 1990) | |
| ps/ | A32 | Madison et al., "Probing Structure—Function relationships of tissue-type plasminogen activator by oligonucleotide-mediated site-specific mutagenesis," <i>Methods in Enzymology</i> 223:249-271 (1993) | |
| ms/ | A33 | Madison et al., "Restoration of serine protease-inhibitor interaction by protein engineering," <i>The Journal of Biological Chemistry</i> 265(35):21423-21426 (December 15, 1990) | |
| | A34 | Madison et al., "Serpin-resistant mutants of human tissue-type plasminogen activator," <i>Nature</i> 339:721-724 (June 29, 1989) | pages cut off, not readable |
| | A35 | Maeda et al., "A novel cell adhesive protein engineered by insertion of the arg-gly-asp-ser tetrapeptide," <i>The Journal of Biological Chemistry</i> 264(26):15165-15168 (September 15, 1989) | ← already at record |
| ms/ | A36 | Mahmoud et al., "Fibrinolysis in insulin dependent diabetic patients with or without nephropathy," <i>Fibrinolysis</i> 6:105-109 (1992) | |
| ms/ | A37 | Mason et al., "Phosphorylation of proteasomes in mammalian cells – identification of two phosphorylated subunits and the effect of phosphorylation on activity," <i>Eur. J. Biochem.</i> 238:453-462 (1996) | |
| | A38 | Rasmi et al., "Making tissue-type plasminogen activator more fibrin-specific," <i>Protein Engin.</i> 6:529-534 (1993) | already at record |
| ms/ | A39 | Pytela et al., "Arginine-glycine-aspartic acid adhesion receptors," <i>Methods in Enzymology</i> 144:475-489 (1987) | |
| ms/ | A40 | Scott et al., "Searching for peptide ligands with an epitope library," <i>Science</i> 249:386-390 (1990) | |
| | A41 | Shin et al., "Chimeric antibody: potential applications for drug delivery and immunotherapy," <i>Biotherapy</i> 3:43-53 (1991) | ← already at record |
| | A42 | Shin et al., "Functional properties of antibody insulin-like growth factor fusion proteins," <i>The Journal of Biological Chemistry</i> 269(7):4979-4985 (1994) | ← already at record |

DLMR254013.1


Examiner
SignatureDate
Considered

2/5/2002

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet

5

of

6

Complete If Known

| | |
|------------------------|----------------------|
| Application Number | 09/091,578 |
| Filing Date | 10/6/1998 |
| First Named Inventor | Edwin L. Madison |
| Group Art Unit | 1644 |
| Examiner Name | Schwadron, Ronald B. |
| Attorney Docket Number | 022726-0201 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|-----------------------------------|
| ms | A43 | Smith et al., "A mechanism for divalent cation regulation of β_3 -integrins," <i>The Journal of Biological Chemistry</i> 269(2):960-967 (January 14, 1994) | |
| | A44 | Smith et al., "Building synthetic antibodies as adhesive ligands for integrins," <i>The Journal of Biological Chemistry</i> 269(52):32788-32795 (December 30, 1994) | already at vision |
| ms | A45 | Smith et al., "Interaction of integrins $\alpha\beta_3$ and glycoprotein IIb-IIIa with fibrinogen," <i>The Journal of Biological Chemistry</i> 265(21):12267-12271 (July 25, 1990) | |
| ms | A46 | Smith et al., "Purification and functional characterization of integrin $\alpha\beta_5$," <i>The Journal of Biological Chemistry</i> 265(19):11008-11013 (July 5, 1990) | |
| ms | A47 | Smith et al., "The arg-gly-asp binding domain of the vitronectin receptor," <i>The Journal of Biological Chemistry</i> 263(35):18726-18731 (December 15, 1988) | |
| ms | A48 | Smith et al., "Purification and functional characterization of integrin $\alpha\beta_5$," <i>The Journal of Biological Chemistry</i> 265(19):11008-11013 (July 5, 1990) | |
| | A49 | Swenson et al., "A platelet targeted thrombolytic agent: covalent modification with a platelet avid peptide," Dept. of Biochemistry, School of Medicine, USC, Los Angeles, CA (Abstract) | Fori Swenson, no journal, no name |
| ms | A50 | Tanaka et al., "The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon- γ -inducible proteasome activator PA28," <i>Immunol. Review</i> 163:161-176 (1998) | |
| ms | A51 | Thomas et al., "Potent interleukin 3 receptor agonist with selectivity enhanced hematopoietic activity relative to recombinant human interleukin 3," <i>Proc. Natl. Acad. Sci. USA</i> 92:3779-3783 (April 1995) | |
| ms | A52 | Van Zonneveld et al., "Autonomous functions of structural domains on human tissue-type plasminogen activator," <i>Proc. Natl. Acad. Sci. USA</i> 83:4670-4674 (July 1986) | |
| ms | A53 | Verheijen et al., "Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin," <i>EMBO Journal</i> 5(13):3525-3530 (1986) | |
| ms | A54 | Yamada et al., "Structure of a conformationally constrained arg-gly-asp sequence inserted into human lysozyme," <i>The Journal of Biological Chemistry</i> 270(11):5687-5690 (1995) | |

DLMR254013.1


Examiner
SignatureDate
Considered

2/5/99

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: _____ <i>(use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 09/091,578 |
| | | Filing Date | 10/6/1998 |
| | | First Named Inventor | Edwin L. Madison |
| | | Group Art Unit | 1644 |
| | | Examiner Name | Schwadron, Ronald B. |
| Sheet | 6 | of | 6 |
| | | Attorney Docket Number | 022726-0201 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
| M | A55 | Zoller et al., "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template," <i>DNA</i> 3(6):479-488 (1984) | |

DLMR254013.1

| | | | |
|-----------------------|--|--------------------|----------|
| Examiner Signature | | Date Considered | 2/5/2001 |
|-----------------------|--|--------------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.